Rydex Biotechnology Fund Class Investor (RYOIX)

Overview

This fund is focused on investing in the vibrant sector of Biotechnology. A significant portion of its assets, at least 80%, is allocated to the equity securities of Biotechnology Companies that operate in the United States. To diversify its investment strategy and possibly hedge against market volatility, the fund also engages in derivative transactions, which primarily include futures contracts and options on securities, futures contracts, and stock indices. It has a keen interest in Biotechnology Companies with small to mid-sized capitalizations, recognizing the growth potential within this segment. Despite its concentrated focus on the Biotechnology sector, the fund operates as non-diversified, meaning it may invest more heavily in a smaller number of securities, potentially increasing its risk and reward profile.

Products and Services

• Equity Securities of Biotechnology Companies:

  This component of the fund's portfolio involves direct investment in the stocks of Biotechnology Companies traded in the United States. By focusing on this sector, the fund aims to capitalize on the growth potential within the biotech industry, especially targeting companies with innovative healthcare solutions and technological advancements in medicine.

• Derivatives Trading:

  The fund engages in derivatives trading as part of its investment strategy. This includes investments in futures contracts and options on securities, futures contracts, and stock indices. Derivatives are financial instruments whose value is derived from the performance of underlying assets, indices, or securities. This approach allows the fund to potentially hedge against market volatility and achieve greater diversification in its investment portfolio.

• Focus on Small to Mid-Sized Biotech Companies:

  Recognizing the unique growth opportunities within smaller companies in the biotechnology sector, the fund places a significant emphasis on investing in Biotechnology Companies with small to mid-sized capitalizations. This strategy leverages the high-growth potential associated with such companies, albeit with a higher risk profile compared to more established firms.